View Item 

Show simple item record

LW106, a novel indoleamine 2,3â dioxygenase 1 inhibitor, suppresses tumour progression by limiting stromaâ immune crosstalk and cancer stem cell enrichment in tumour microâ environment
dc.contributor.authorFu, Rong
dc.contributor.authorZhang, Yi‐wei
dc.contributor.authorLi, Hong‐mei
dc.contributor.authorLv, Wen‐cong
dc.contributor.authorZhao, Li
dc.contributor.authorGuo, Qing‐long
dc.contributor.authorLu, Tao
dc.contributor.authorWeiss, Stephen J
dc.contributor.authorLi, Zhi‐yu
dc.contributor.authorWu, Zhao‐qiu
dc.date.accessioned2018-07-13T15:48:18Z
dc.date.available2019-09-04T20:15:39Zen
dc.date.issued2018-07
dc.identifier.citationFu, Rong; Zhang, Yi‐wei ; Li, Hong‐mei ; Lv, Wen‐cong ; Zhao, Li; Guo, Qing‐long ; Lu, Tao; Weiss, Stephen J; Li, Zhi‐yu ; Wu, Zhao‐qiu (2018). "LW106, a novel indoleamine 2,3â dioxygenase 1 inhibitor, suppresses tumour progression by limiting stromaâ immune crosstalk and cancer stem cell enrichment in tumour microâ environment." British Journal of Pharmacology 175(14): 3034-3049.
dc.identifier.issn0007-1188
dc.identifier.issn1476-5381
dc.identifier.urihttps://hdl.handle.net/2027.42/144686
dc.publisherWiley Periodicals, Inc.
dc.titleLW106, a novel indoleamine 2,3â dioxygenase 1 inhibitor, suppresses tumour progression by limiting stromaâ immune crosstalk and cancer stem cell enrichment in tumour microâ environment
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPharmacy and Pharmacology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/144686/1/bph14351.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/144686/2/bph14351_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/144686/3/bph14351-sup-0001-supplementary_information.pdf
dc.identifier.doi10.1111/bph.14351
dc.identifier.sourceBritish Journal of Pharmacology
dc.identifier.citedreferenceMunn DH, Mellor AL ( 2007 ). Indoleamine 2,3â dioxygenase and tumorâ induced tolerance. J Clin Invest 117: 1147 â 1154.
dc.identifier.citedreferenceJoyce JA, Pollard JW ( 2009 ). Microenvironmental regulation of metastasis. Nat Rev Cancer 9: 239 â 252.
dc.identifier.citedreferenceKilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG ( 2010 ). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577 â 1579.
dc.identifier.citedreferenceLiu X, Shin N, Koblish HK, Yang G, Wang Q, Wang K et al. ( 2010 ). Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood 115: 3520 â 3530.
dc.identifier.citedreferenceLu P, Takai K, Weaver VM, Werb Z ( 2011 ). Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb Perspect Biol 3: a005058.
dc.identifier.citedreferenceMellor AL, Baban B, Chandler P, Marshall B, Jhaver K, Hansen A et al. ( 2003 ). Induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J Immunol 171: 1652 â 1655.
dc.identifier.citedreferenceMcGrath JC, Lilley E ( 2015 ). Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. Br J Pharmacol 172: 3189 â 3193.
dc.identifier.citedreferenceMunn DH, Mellor AL ( 2004 ). IDO and tolerance to tumors. Trans. Mol Med 10: 15 â 18.
dc.identifier.citedreferenceMunn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL ( 1999 ). Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 189: 1363 â 1372.
dc.identifier.citedreferenceMunn DH, Sharma MD, Baban B, Harding HP, Zhang Y, Ron D et al. ( 2005 ). GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3â dioxygenase. Immunity 22: 633 â 642.
dc.identifier.citedreferenceMunn DH, Sharma MD, Lee JR, Jhaver KG, Johnson TS, Keskin DB et al. ( 2002 ). Potential regulatory function of human dendritic cells expressing indoleamine 2,3â dioxygenase. Science 297: 1867 â 1870.
dc.identifier.citedreferenceNi T, Li Xâ Y, Lu N, An T, Liu Zâ P, Fu R et al. ( 2016 ). Snail1â dependent p53 repression regulates expansion and activity of Tumorâ initiating cells in breast cancer. Nat Cell Biol 18: 1221 â 1232.
dc.identifier.citedreferencePan K, Wang H, Chen MS, Zhang HK, Weng DS, Zhou J et al. ( 2008 ). Expression and prognosis role of indoleamine 2,3â dioxygenase in hepatocellular carcinoma. J Cancer Res Clin Oncol 134: 1247 â 1253.
dc.identifier.citedreferencePolak ME, Borthwich NJ, Gabriel FG, Johnson P, Higgins B, Hurren J et al. ( 2007 ). Mechanisms of local immunosuppression in cutaneous melanoma. Br J Cancer 96: 1879 â 1887.
dc.identifier.citedreferencePrendergast GC ( 2008 ). Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene 27: 3889 â 3900.
dc.identifier.citedreferenceProvenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR ( 2012 ). Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21: 418 â 429.
dc.identifier.citedreferenceSalmon H, Franciszkiewicz K, Damotte D, Dieuâ Nosjean MC, Validire P, Trautmann A et al. ( 2012 ). Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung Tumors. J Clin Invest 122: 899 â 910.
dc.identifier.citedreferenceSono M, Hayaishi O ( 1980 ). The reaction mechanism of indoleamine 2,3â dioxygenase. Biochem Rev 50: 173 â 181.
dc.identifier.citedreferenceSono M, Roach MP, Coulter ED, Dawson JH ( 1996 ). Hemeâ containing oxygenases. Chem Rev 96: 2841 â 2888.
dc.identifier.citedreferenceSzasz AM, Lanczky A, Nagy A, Forster S, Hark K, Green JE et al. ( 2016 ). Crossâ validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. Oncotarget 7: 49322 â 49333.
dc.identifier.citedreferenceTan W, Zhang W, Strasner A, Grivennikov S, Cheng JQ, Hoffman RM et al. ( 2011 ). Tumorâ infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKLâ RANK signaling. Nature 470: 548 â 553.
dc.identifier.citedreferenceTurley SJ, Cremasco V, Astarita JL ( 2015 ). Immunological hallmarks of stromal cells in the tumor microenvironment. Nat Rev Immunol 15: 669 â 682.
dc.identifier.citedreferenceAlexander SPH, Fabbro D, Kelly E, Marrion NV, Peters JA, Faccenda E et al. ( 2017 ). The Concise Guide to PHARMACOLOGY 2017/18: Enzymes. Br J Pharmacol 174: S272 â S359.
dc.identifier.citedreferenceBeatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W et al. ( 2011 ). CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331: 1612 â 1616.
dc.identifier.citedreferenceBhowmich NA, Neilson EG, Moses HL ( 2004 ). Stromal fibroblasts in cancer initiation and progression. Nature 432: 332 â 337.
dc.identifier.citedreferenceBotting NP ( 1995 ). Chemistry and neurochemistry of kynurenine pathway of tryptophan metabolism. Chem Soc Rev 24: 401 â 412.
dc.identifier.citedreferenceBrandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P, Winkler C et al. ( 2006 ). Prognostic value of indoleamine 2,3â dioxygenase expression in colorectal cancer: effect on tumorâ infiltrating T cells. Clin Cancer Res 12: 1144 â 1151.
dc.identifier.citedreferenceBuckanovich RJ, Facciabene A, Kim S, Benencia F, Sasaroli D, Balint K et al. ( 2008 ). Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med 14: 28 â 36.
dc.identifier.citedreferenceCady SG, Sono M ( 1991 ). 1â methylâ DLâ tryptophan, βâ (3â benzofurany)â DLâ alanine, and βâ [3â benzo(b)thienyl]â DLâ alanine are competitive inhibitors for indoleamine 2,3â dioxygenase. Arch Biochem Biophys 291: 326 â 333.
dc.identifier.citedreferenceCaruana I, Savoldo B, Hoyos V, Weber G, Liu H, Kim ES et al. ( 2015 ). Heparanase promotes tumor infiltration and antitumor activity of CARâ redirected T lymphocytes. Nat Med 21: 524 â 529.
dc.identifier.citedreferenceCastermans K, Griffioen AW ( 2007 ). Tumor blood vessels, a difficult hurdle for infiltrating leukocytes. Biochem Biophys Acta 1776: 160 â 174.
dc.identifier.citedreferenceCodonyâ Servat J, Verlicchi A, Rosell R ( 2016 ). Cancer stem cells in small cell lung cancer. Transl Lung Cancer Res 5: 16 â 25.
dc.identifier.citedreferenceCoussen LM, Werb Z ( 2002 ). Inflammation and cancer. Nature 420: 860 â 867.
dc.identifier.citedreferenceCoussens LM, Zitvogel L, Palucka AK ( 2013 ). Neutralizing tumor promising chronic inflammation: a magic bullet? Science 339: 286 â 291.
dc.identifier.citedreferenceCurtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SP, Giembycz MA et al. ( 2015 ). Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol 172: 3461 â 3471.
dc.identifier.citedreferenceEleftheriadis T, Pissas G, Antoniadi G, Spanoulis A, Liakopoulos V, Stefanidis L ( 2014 ). Indoleamine 2,3â dioxygenase increases p53 levels in alloreactive human T cells, and both indoleamine 2,3â dioxygenase and p53 suppress glucose uptake, glycolysis and proliferation. Int Immunol 26: 673 â 684.
dc.identifier.citedreferenceFallarino F, Grohmann U, Vacca C, Bianchi R, Orabona C, Spreca A et al. ( 2002 ). T cell apoptosis by tryptophan catabolism. Cell Death Differ 9: 1069 â 1077.
dc.identifier.citedreferenceFeig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS et al. ( 2013 ). Targeting CXCL12 from FAPâ expressing carcinomaâ associated fibroblasts synergizes with antiâ PDâ L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A 110: 20212 â 20217.
dc.identifier.citedreferenceFrumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB ( 2002 ). Tryptophanâ derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3â dioxygenase. J Exp Med 196: 459 â 468.
dc.identifier.citedreferenceGyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q et al. ( 2010 ). An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1809 patients. Breast Cancer Res Treat 123: 725 â 731.
dc.identifier.citedreferenceGyorffy B, Lanczky A, Szallasi Z ( 2012 ). Implementing an online tool for genomeâ wide validation of survivalâ associated biomarkers in ovarianâ cancer using microarray data of 1287 patients. Endocrâ Relat Cancer 19: 197 â 208.
dc.identifier.citedreferenceGyorffy B, Surowiak P, Budczies J, Lanczky A ( 2013 ). Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in nonâ smallâ cell lung cancer. PLoS ONE 8: e82241.
dc.identifier.citedreferenceHanahan D, Coussens LM ( 2012 ). Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21: 309 â 322.
dc.identifier.citedreferenceHardavella G, George R, Sethi T ( 2016 ). Lung cancer stem cellsâ characteristics, phenotype. Transl Lung Cancer Res 5: 272 â 279.
dc.identifier.citedreferenceHarding SD, Sharman JL, Faccenda E, Southan C, Pawson AJ, Ireland S et al. ( 2018 ). The IUPHAR/BPS guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. Nucl Acids Res 46: D1091 â D1106.
dc.identifier.citedreferenceHanahan D, Weinberg RA ( 2011 ). Hallmarks of cancer: the next generation. Cell 144: 646 â 674.
dc.identifier.citedreferenceHolmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP ( 2013 ). Indoleamine 2,3â dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLAâ 4. J Exp Med 210: 1389 â 1402.
dc.identifier.citedreferenceIno K, Yamamoto E, Shibata K, Kajiyama H, Yoshida N, Terauchi M et al. ( 2008 ). Inverse correlation between tumoral indoleamine 2,3â dioxygenase expression and tumorâ infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival. Clin Cancer Res 14: 2310 â 2317.
dc.identifier.citedreferenceJackson E, Dees EC, Kauh JS, Harvey RD, Neuger A, Lush R et al. ( 2013 ). A phase I study of indoximod in combination with docetaxel in metastatic solid tumors. 2013 ASCO Annual Meeting. J Clin Oncol 31 ( suppl ) abstr 3026.
dc.identifier.citedreferenceJohansson M, Denardo DG, Coussens LM ( 2008 ). Polarized immune responses differentially regulate cancer development. Immunol Rev 222: 145 â 154.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
bph14351.pdf
Size:
2.121MB
Format:
PDF
View/Open
Name:
bph14351_am.pdf
Size:
11.27MB
Format:
PDF
View/Open
Name:
bph14351-sup-0001-supplementar ...
Size:
13.00MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.